Acerux IV Infusion 500 mg/vial

Acerux IV Infusion is an antiviral medication manufactured by Opsonin Pharma Ltd, containing 500 mg/vial of the active ingredient Acyclovir. Priced at ৳700.00 per vial, it treats severe herpes infections through intravenous administration. The solution must be stored between 15°C to 25°C, protected from light and moisture, and kept away from children.

This IV Infusion is prescribed for immunocompromised patients with herpes simplex, severe genital herpes, shingles, and herpes encephalitis. It inhibits viral DNA synthesis, stopping replication. Dosage varies: 5-10 mg/kg every 8 hours, infused slowly over one hour. Always consult a doctor for personalized regimens.

Key indications include:

• Herpes simplex in immunocompromised adults
• Life-threatening herpes encephalitis
• Severe shingles with systemic complications
• Varicella-zoster in vulnerable patients

Potential side effects range from nausea, dizziness, and skin rashes to rare neurological symptoms like seizures. Drug interactions with probenecid or diuretics may require dose adjustments. Pregnant/nursing women should use it cautiously after risk-benefit analysis.

Acerux 500 mg/vial offers a critical therapeutic option for herpes management. For alternatives like Acerux 250 mg/vial or detailed Acyclovir information, consult healthcare providers or trusted pharmacies.

Adults: 5 mg/kg every 8h for herpes, 10 mg/kg for encephalitis. Pediatric dose: 250-500 mg/m² based on BSA. Renal impairment requires interval extension (CrCl 25-50: 12h, CrCl 10-25: 24h). Administer as 1-hour IV infusion.

Some infrequent adverse reactions are lethargy, obtundation, tremors, confusion, hallucinations, agitation, somnolence, psychosis, convulsions and coma, phlebitis, nausea, vomiting, reversible increases in liver-related enzymes, pruritus, urticaria, rashes, increases in blood urea and creatinine. Local inflammatory reactions may occur if Acerux IV Infusion is inadvertently infused into extracellular tissues.

Pregnancy Category B: Use only if benefits outweigh risks. Breastfeeding requires risk-benefit assessment.

Maintain hydration during infusion. Monitor neurological status in predisposed patients. Strictly avoid rapid bolus administration.

Pediatrics: Dose by BSA (250 mg/m²). Geriatrics: Reduce dose based on CrCl. Renal impairment: Extend dosing intervals per CrCl levels.

Overdosage of intravenous Acerux has resulted in elevations of serum creatinine, blood urea nitrogen and subsequent renal failure. Neurological effects including confusion, hallucinations, agitation, seizures and coma have been described in association with over dosage. Adequate hydration is essential to reduce the possibility of crystal formation in the urine. Hemodialysis significantly enhances the removal of Acerux from the blood and may, therefore, be considered an option in the management of overdose of Acerux.